Edinburgh-based Trogenix closed a $95 million Series A co-led by IQ Capital to advance its Odysseus platform into human studies for aggressive solid tumors, the company said. Odysseus uses synthetic super-enhancers delivered by AAV vectors to selectively activate therapeutic payloads inside cancer cells, combining localized prodrug activation with immune-stimulatory cytokines. Investors including Eli Lilly and the National Brain Tumor Society participated. Trogenix plans a first-in-human glioblastoma program anticipated in Q1 2026 and follow-on studies in colorectal liver metastases, highlighting continued investor appetite for innovative vector-based strategies targeting hard-to-treat solid tumors.